Advice
Following a resubmission:
crizotinib (Xalkori®) is accepted for use within NHS Scotland.
Indication under review: treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
In a phase III clinical study in patients with previously treated anaplastic lymphoma kinase (ALK)-positive advanced NSCLC, crizotinib significantly increased progression-free survival compared with standard chemotherapy.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of crizotinib. This SMC advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice181KB (PDF)
Medicine details
- Medicine name:
- crizotinib (Xalkori)
- SMC ID:
- 865/13
- Indication:
- For the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 07 October 2013